These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20173677)

  • 21. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults.
    Aguilar-Betancourt A; González-Delgado CA; Cinza-Estévez Z; Martínez-Cabrera J; Véliz-Ríos G; Alemán-Zaldívar R; Alonso-Martínez MI; Lago-Baños M; Puble-Alvarez N; Delahanty-Fernandez A; Juvier-Madrazo AI; Ortega-León D; Olivera-Ruano L; Correa-Fernández A; Abreu-Reyes D; Soto-Mestre E; Pérez-Pérez MV; Figueroa-Baile N; Pérez LH; Rodríguez-Silva A; Martínez-Díaz E; Guillén-Nieto GE; Muzio-González VL
    Hum Vaccin; 2008; 4(1):54-9. PubMed ID: 18441530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunisation against hepatitis A, hepatitis B and typhoid fever via combined vaccination: rationale, immunogenicity and reactogenicity.
    Proell S
    BioDrugs; 2003; 17 Suppl 1():7-10. PubMed ID: 12785871
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.
    Young MD; Gooch WM; Zuckerman AJ; Du W; Dickson B; Maddrey WC
    J Med Virol; 2001 Jul; 64(3):290-8. PubMed ID: 11424117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial.
    Østergaard L; Silfverdal SA; Berglund J; Flodmark CE; West C; Bianco V; Baine Y; Miller JM
    Vaccine; 2012 Jan; 30(4):774-83. PubMed ID: 22107850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.
    Leroux-Roels G; Abraham B; Fourneau M; De Clercq N; Safary A
    Vaccine; 2000 Nov; 19(7-8):937-42. PubMed ID: 11115719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response to hepatitis B vaccination in urban, homeless adults.
    Jones T; Nyamathi A; Giger JN; Jacobsen SJ
    J Natl Black Nurses Assoc; 2007 Jul; 18(1):1-7. PubMed ID: 17679408
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunogenicity and safety of combined intradermal recombinant Hepatitis B with BCG vaccines at birth.
    Carniel EF; Morcillo AM; Blotta MH; Da Silva MT; Mazzola TN; Antonio MA; Zanolli ML; Netto AA; Higashi HG; Raw I; Vilela MM
    Vaccine; 2008 Jan; 26(5):647-52. PubMed ID: 18155811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.
    Cassidy WM; Watson B; Ioli VA; Williams K; Bird S; West DJ
    Pediatrics; 2001 Apr; 107(4):626-31. PubMed ID: 11335734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.
    Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F;
    Lancet Infect Dis; 2015 Nov; 15(11):1283-91. PubMed ID: 26257021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.
    Van Damme P; Leroux-Roels G; Suryakiran P; Folschweiller N; Van Der Meeren O
    Hum Vaccin Immunother; 2017 May; 13(5):972-980. PubMed ID: 28281907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
    Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
    J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents.
    Beran J; Kervyn D; Wertzova V; Hobzova L; Tichy P; Kuriyakose S; Leyssen M; Jacquet JM
    Vaccine; 2010 Aug; 28(37):5993-7. PubMed ID: 20637766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
    Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E;
    Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.
    Losonsky GA; Wasserman SS; Stephens I; Mahoney F; Armstrong P; Gumpper K; Dulkerian S; West DJ; Gewolb IH
    Pediatrics; 1999 Feb; 103(2):E14. PubMed ID: 9925860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years.
    Levie K; Beran J; Collard F; Nguyen C
    Vaccine; 2002 Jun; 20(19-20):2579-84. PubMed ID: 12057615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults.
    Rustgi VK; Schleupner CJ; Krause DS
    Vaccine; 1995 Dec; 13(17):1665-8. PubMed ID: 8719517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.